Sign in Subscribe
Class action lawsuits

Novo Nordisk A/S Shareholders Encouraged to Contact The Gross Law Firm Regarding Class Action

Strategic Insights

— 1 min read

The Gross Law Firm has issued a notice to shareholders of Novo Nordisk A/S (NYSE: NVO) who purchased shares during the class period of May 7, 2025 to July 28, 2025. The firm is investigating claims that defendants made false and misleading statements to investors about the company's growth potential, particularly regarding the impact of the personalization exception to the compounded GLP-1 exclusion and the likelihood of patients switching to Novo's branded alternatives.

Key Takeaways:

  • The Gross Law Firm is investigating claims that Novo Nordisk A/S made false and misleading statements to investors about the company's growth potential.
  • The firm alleges that Novo provided overwhelmingly positive statements to investors while concealing material adverse facts concerning the true state of the company's growth potential.
  • The company attributed its lowered sales and profit outlook on "lowered growth expectations for the second half of 2025" due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition."
  • The price of Novo's common stock declined dramatically following the news, falling from $69.00 per share on July 28, 2025 to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day.
  • The Gross Law Firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by Novo lead to artificial inflation of the company's stock.
  • The deadline to seek to be a lead plaintiff is September 30, 2025.
  • Shareholders should not delay in registering for this class action to be eligible for the potential recovery.

Statistics:

  • The price of Novo's common stock fell approximately 21.83% in a single day (July 28, 2025 to July 29, 2025).
  • The price of Novo's common stock fell from $69.00 per share on July 28, 2025 to $53.94 per share on July 29, 2025.
  • The class period listed is May 7, 2025 to July 28, 2025.

Sources:

  • GlobeNewswire: "The Gross Law Firm Announces Investigation into Novo Nordisk A/S (NYSE: NVO)" August 27, 2025

Read more